Published in Clin Cancer Res on October 15, 2005
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics (2008) 3.11
Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev (2009) 2.98
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Modeling cancer progression via pathway dependencies. PLoS Comput Biol (2008) 2.12
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell (2015) 2.10
Targeting SphK1 as a new strategy against cancer. Curr Drug Targets (2008) 1.91
Large-scale integration of cancer microarray data identifies a robust common cancer signature. BMC Bioinformatics (2007) 1.74
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J (2011) 1.66
Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One (2008) 1.63
BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res (2013) 1.43
Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci U S A (2007) 1.43
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest (2010) 1.41
Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex. Cell Death Differ (2009) 1.35
The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol (2009) 1.31
Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am J Pathol (2010) 1.31
Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc (2009) 1.25
HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets (2009) 1.25
Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish. Zebrafish (2009) 1.24
Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog (2010) 1.24
Suppression of survival signalling pathways by the phosphatase PHLPP. FEBS J (2012) 1.23
A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One (2009) 1.21
Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem (2011) 1.21
Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci U S A (2012) 1.18
Microarray-based cancer prediction using single genes. BMC Bioinformatics (2011) 1.16
Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma. Mol Cell (2015) 1.13
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. J Transl Med (2007) 1.12
Common human cancer genes discovered by integrated gene-expression analysis. PLoS One (2007) 1.11
Genome-wide association study identifies nidogen 1 (NID1) as a susceptibility locus to cutaneous nevi and melanoma risk. Hum Mol Genet (2011) 1.10
Modulation of extracellular matrix/adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness. Mol Cancer (2010) 1.10
Protein kinase C and cancer: what we know and what we do not. Oncogene (2013) 1.09
Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget (2015) 1.09
Protein kinase Cι expression and oncogenic signaling mechanisms in cancer. J Cell Physiol (2011) 1.08
Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nat Commun (2014) 1.08
PGC-1 coactivators regulate MITF and the tanning response. Mol Cell (2012) 1.07
Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling. J Biol Chem (2011) 1.04
Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. Biochim Biophys Acta (2008) 1.03
Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget (2012) 1.02
Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc Natl Acad Sci U S A (2007) 1.02
Klotho is silenced through promoter hypermethylation in gastric cancer. Am J Cancer Res (2010) 1.01
Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Invest Dermatol (2013) 1.00
Biological assessment of robust noise models in microarray data analysis. Bioinformatics (2011) 1.00
The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med (2008) 0.99
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer (2011) 0.99
Comparative evaluation of set-level techniques in predictive classification of gene expression samples. BMC Bioinformatics (2012) 0.98
Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia (2009) 0.98
Slug expression during melanoma progression. Am J Pathol (2012) 0.97
Gene expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion. Br J Cancer (2010) 0.97
The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. Am J Pathol (2009) 0.97
A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene (2012) 0.96
Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol (2007) 0.96
Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10. Biochem Biophys Res Commun (2010) 0.96
Ion channels expression and function are strongly modified in solid tumors and vascular malformations. J Transl Med (2016) 0.96
E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle (2012) 0.96
Methylation and loss of Secreted Frizzled-Related Protein 3 enhances melanoma cell migration and invasion. PLoS One (2011) 0.95
Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology (2010) 0.95
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci U S A (2013) 0.95
PCTAIRE1 regulates p27 stability, apoptosis and tumor growth in malignant melanoma. Oncoscience (2014) 0.95
The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One (2011) 0.94
Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med (2007) 0.92
Robust multi-tissue gene panel for cancer detection. BMC Cancer (2010) 0.91
Coordination of nutrient availability and utilization by MAX- and MLX-centered transcription networks. Cold Spring Harb Perspect Med (2013) 0.91
RNA polymerase III transcription in cancer: the BRF2 connection. Mol Cancer (2011) 0.91
Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation. Transl Oncol (2009) 0.91
Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol (2010) 0.91
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma. J Histochem Cytochem (2011) 0.90
Distinct pigmentary and melanocortin 1 receptor-dependent components of cutaneous defense against ultraviolet radiation. PLoS Genet (2006) 0.90
The hematopoietic stem cell regulatory gene latexin has tumor-suppressive properties in malignant melanoma. J Invest Dermatol (2013) 0.89
T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res (2013) 0.89
Cell cycle gene networks are associated with melanoma prognosis. PLoS One (2012) 0.88
Human mitochondrial NAD(P)(+)-dependent malic enzyme participates in cutaneous melanoma progression and invasion. J Invest Dermatol (2014) 0.87
USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics. Cell Death Differ (2015) 0.87
Detection of Exosomal miRNAs in the Plasma of Melanoma Patients. J Clin Med (2015) 0.87
Tissue-specific gene expression templates for accurate molecular characterization of the normal physiological states of multiple human tissues with implication in development and cancer studies. BMC Genomics (2011) 0.86
Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins. BMC Cancer (2010) 0.86
Dual Roles of RNF2 in Melanoma Progression. Cancer Discov (2015) 0.86
Conserved expression signatures between medaka and human pigment cell tumors. PLoS One (2012) 0.84
Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. Oncotarget (2014) 0.84
Sds22/PP1 links epithelial integrity and tumor suppression via regulation of myosin II and JNK signaling. Oncogene (2011) 0.83
Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention. Oncotarget (2013) 0.83
Tumor-specific silencing of COPZ2 gene encoding coatomer protein complex subunit ζ 2 renders tumor cells dependent on its paralogous gene COPZ1. Proc Natl Acad Sci U S A (2011) 0.83
Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. J Immunol (2009) 0.83
Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clin Exp Metastasis (2011) 0.82
A PGC1α-mediated transcriptional axis suppresses melanoma metastasis. Nature (2016) 0.82
ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. Mol Cancer Res (2015) 0.81
The C. elegans SoxC protein SEM-2 opposes differentiation factors to promote a proliferative blast cell fate in the postembryonic mesoderm. Development (2011) 0.81
Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma. PLoS One (2015) 0.81
Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. Oncogene (2015) 0.81
HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin. Mol Cell Biol (2015) 0.80
SKINOMICS: Transcriptional Profiling in Dermatology and Skin Biology. Curr Genomics (2012) 0.80
Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions. Cancer Res (2014) 0.80
WLS inhibits melanoma cell proliferation through the β-catenin signalling pathway and induces spontaneous metastasis. EMBO Mol Med (2012) 0.80
Organization, evolution and functions of the human and mouse Ly6/uPAR family genes. Hum Genomics (2016) 0.79
A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity. Cell Death Dis (2015) 0.79
Hypoxic induction of AKAP12 variant 2 shifts PKA-mediated protein phosphorylation to enhance migration and metastasis of melanoma cells. Proc Natl Acad Sci U S A (2015) 0.79
UFFizi: a generic platform for ranking informative features. BMC Bioinformatics (2010) 0.78
Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche. Int J Cancer (2015) 0.78
Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Mol Cell (2016) 0.78
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol (2011) 5.10
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
Subtypes of breast cancer show preferential site of relapse. Cancer Res (2008) 4.38
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol (2010) 3.60
GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol (2011) 3.44
GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol (2011) 3.30
Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol (2002) 3.23
Genes associated with breast cancer metastatic to bone. J Clin Oncol (2006) 3.21
Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol (2004) 3.04
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol (2008) 2.78
AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol (2010) 2.63
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol (2006) 2.48
An assessment of Motorola CodeLink microarray performance for gene expression profiling applications. Nucleic Acids Res (2002) 2.37
The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2003) 2.31
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem (2010) 1.97
GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol (2012) 1.90
Making evidence from research more relevant, useful, and actionable in policy, program planning, and practice slips "twixt cup and lip". Am J Prev Med (2009) 1.78
Employer coverage of clinical preventive services in the United States. Am J Health Promot (2006) 1.77
Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer (2007) 1.75
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat (2008) 1.68
mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res (2011) 1.66
AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol (2008) 1.57
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood (2011) 1.56
Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol (2009) 1.56
Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat (2010) 1.52
Melanoma-specific marker expression in skin biopsy tissues as a tool to facilitate melanoma diagnosis. J Invest Dermatol (2010) 1.52
Oligodeoxyribonucleotide probe accessibility on a three-dimensional DNA microarray surface and the effect of hybridization time on the accuracy of expression ratios. BMC Biotechnol (2003) 1.49
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood (2007) 1.48
Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate (2008) 1.46
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat (2008) 1.34
Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res (2009) 1.33
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer (2004) 1.31
A highly reproducible, linear, and automated sample preparation method for DNA microarrays. Genome Res (2002) 1.27
Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One (2009) 1.25
Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn (2008) 1.17
KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer (2013) 1.16
AHRQ series paper 1: comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol (2008) 1.15
Left behind: the legacy of hurricane Katrina. BMJ (2005) 1.08
A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn (2006) 1.08
Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative. J Mol Diagn (2006) 1.06
Challenges in using nonrandomized studies in systematic reviews of treatment interventions. Ann Intern Med (2005) 1.05
Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem (2002) 1.00
Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov (2011) 1.00
Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem (2008) 0.99
Observational studies in systematic [corrected] reviews of comparative effectiveness: AHRQ and the Effective Health Care Program. J Clin Epidemiol (2011) 0.99
Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res (2007) 0.95
Expression profiling with oligonucleotide arrays: technologies and applications for neurobiology. Neurochem Res (2002) 0.94
Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. Breast Cancer Res Treat (2011) 0.93
Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer (2012) 0.92
Use of health information technology to advance evidence-based care: lessons from the VA QUERI program. J Gen Intern Med (2010) 0.90
QUERI and implementation research: emerging from adolescence into adulthood: QUERI Series. Implement Sci (2009) 0.89
Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate (2012) 0.87
The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine. Drug Discov Today (2008) 0.86
Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis. J Mol Diagn (2005) 0.85
Gene expression profiles and prognostic markers for primary breast cancer. Methods Mol Biol (2007) 0.85
Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. J Urol (2011) 0.85
Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol (2011) 0.83
New disease: motivational deficiency disorder: study ignores economic benefits. BMJ (2006) 0.83
Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Mol Pharm (2015) 0.83
Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy. J Urol (2010) 0.83
A smooth response surface algorithm for constructing a gene regulatory network. Physiol Genomics (2002) 0.82
Gene-expression signatures in oncology diagnostics. Pharmacogenomics (2006) 0.80
Partner or perish: VA health services and the emerging bi-directional paradigm. J Gen Intern Med (2014) 0.80
Photonic crystal fiber tip interferometer for refractive index sensing. Opt Lett (2012) 0.79
The risk of aprotinin: a conflict of evidence. Lancet (2006) 0.79
Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc (2012) 0.78
Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2009) 0.78
Implementation of a new screening recommendation in health care: the Veterans Health Administration's approach to lung cancer screening. Ann Intern Med (2014) 0.78
Validation and integration of gene-expression signatures in cancer. Expert Rev Mol Diagn (2008) 0.78
Tuning indium tin oxide work function with solution-processed alkali carbonate interfacial layers for high-efficiency inverted organic photovoltaic cells. Nanotechnology (2013) 0.78
Automated multiplexing quantum dots in situ hybridization assay for simultaneous detection of ERG and PTEN gene status in prostate cancer. J Mol Diagn (2013) 0.77
Health services research on women veterans: a critical partner on the road to patient-centered care. J Gen Intern Med (2013) 0.77
[The relation of metastasis and prognosis with transforming growth factor-beta1 and E-cadherin expression in supraglottic larynx squamous cell carcinoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi (2006) 0.77
Allele-specific, non-extendable primer blocker PCR (AS-NEPB-PCR) for DNA mutation detection in cancer. J Mol Diagn (2012) 0.77
Priority setting in guideline development: article 2 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc (2012) 0.77